The estimated Net Worth of Thomas Watkins is at least $13.4 Million dollars as of 29 September 2023. Mr. Watkins owns over 81,323 units of Horizon Therapeutics Plc stock worth over $12,844,986 and over the last 18 years he sold HZNP stock worth over $0. In addition, he makes $515,215 as Independent Director at Horizon Therapeutics Plc.
H has made over 12 trades of the Horizon Therapeutics Plc stock since 2014, according to the Form 4 filled with the SEC. Most recently he exercised 81,323 units of HZNP stock worth $1,106,806 on 29 September 2023.
The largest trade he's ever made was exercising 81,323 units of Horizon Therapeutics Plc stock on 29 September 2023 worth over $1,106,806. On average, H trades about 5,674 units every 87 days since 2006. As of 29 September 2023 he still owns at least 110,447 units of Horizon Therapeutics Plc stock.
You can see the complete history of Mr. Watkins stock trades at the bottom of the page.
H. Thomas Watkins is Independent Director of the Company. Mr. Watkins currently serves as the chairman of the board of directors of Vanda Pharmaceuticals, Inc., a public biopharma company. Prior to that, he was director, president and chief executive officer of Human Genome Sciences, Inc. (HGS), a public biopharma company, from 2004 until HGS was acquired by GlaxoSmithKline in 2012. Before leading HGS, Mr. Watkins spent over twenty years in senior roles at Abbott Laboratories and its affiliates in the United States and Asia, most recently serving as the president of TAP Pharmaceutical Products, Inc. (TAP), which was jointly owned by Abbott and Takeda Pharmaceutical Company, Inc. During his tenure, he led the growth of TAP from approximately $2 billion to over $4 billion in annual revenue. Mr. Watkins began his career in 1974 with Arthur Andersen & Co. From 1979 to 1985, he was a management consultant with McKinsey and Company, Inc., working with multinational companies in the United States, Europe and Japan. Mr. Watkins holds a bachelor’s degree from the College of William and Mary, and a master of business administration degree from the University of Chicago Graduate School of Business.
As the Independent Director of Horizon Therapeutics Plc, the total compensation of H Watkins at Horizon Therapeutics Plc is $515,215. There are 10 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.
H Watkins is 67, he's been the Independent Director of Horizon Therapeutics Plc since 2014. There are no older and 22 younger executives at Horizon Therapeutics Plc.
Thomas's mailing address filed with the SEC is C/O HORIZON THERAPEUTICS PLC,, 70 ST. STEPHEN?S GREEN, DUBLIN, L2, D02 E2X4.
Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F..., and Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.
at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.
Horizon Therapeutics Plc executives and other stock owners filed with the SEC include: